▶ 調査レポート

世界の結核治療市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global Tuberculosis Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の結核治療市場 2021:企業別、地域別、種類・用途別 / Global Tuberculosis Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026 / GIR-2104Z14260資料のイメージです。• レポートコード:GIR-2104Z14260
• 出版社/出版日:GlobalInfoResearch / 2021年4月
※2025年版があります。お問い合わせください。

• レポート形態:英文、PDF、103ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥504,600 (USD3,480)▷ お問い合わせ
  Multi User¥756,900 (USD5,220)▷ お問い合わせ
  Corporate User¥1,009,200 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、結核治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。結核治療の種類別市場規模(イソニアジド、リファンピン、ピラジナミド、ヒドラジン誘導体、その他抗尿細管薬、エタンブトール、その他)、用途別市場規模(病院、薬局、診療所、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・結核治療の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):Aventis Pharmaceuticals、Sanofi -Aventis、Versapharma Incorporated、Sigma Pharmaceutical Pty、Novartis AG、Hoffmann-La Roche、Bayer Health Care
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:イソニアジド、リファンピン、ピラジナミド、ヒドラジン誘導体、その他抗尿細管薬、エタンブトール、その他
・用途別分析2016年-2026年:病院、薬局、診療所、その他
・結核治療の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・結核治療のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・結核治療のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・結核治療の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・結核治療の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Tuberculosis Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Tuberculosis Therapeutics size is estimated to be USD 965.3 million in 2025 from USD 863.6 million in 2019, with a change XX% between 2019 and 2020. The global Tuberculosis Therapeutics market size is expected to grow at a CAGR of 2.8% for the next five years.

Market segmentation
Tuberculosis Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Isoniazid
Rifampin
Pyrazinamide
Hydrazine Derivatives
Miscellaneous Anti-Tubercular Drugs
Ethambutol
Others

Market segment by Application, can be divided into
Hospital
Pharmacy
Clinics
Others

Market segment by players, this report covers
Aventis Pharmaceuticals
Sanofi -Aventis
Versapharma Incorporated
Sigma Pharmaceutical Pty
Novartis AG
Hoffmann-La Roche
Bayer Health Care

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Tuberculosis Therapeutics
1.2 Classification of Tuberculosis Therapeutics by Type
1.2.1 Overview: Global Tuberculosis Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Tuberculosis Therapeutics Revenue Market Share by Type in 2020
1.2.3 Isoniazid
1.2.4 Rifampin
1.2.5 Pyrazinamide
1.2.6 Hydrazine Derivatives
1.2.7 Miscellaneous Anti-Tubercular Drugs
1.2.8 Ethambutol
1.2.9 Others
1.3 Global Tuberculosis Therapeutics Market by Application
1.3.1 Overview: Global Tuberculosis Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Clinics
1.3.5 Others
1.4 Global Tuberculosis Therapeutics Market Size & Forecast
1.5 Global Tuberculosis Therapeutics Market Size and Forecast by Region
1.5.1 Global Tuberculosis Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Tuberculosis Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Tuberculosis Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Tuberculosis Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Tuberculosis Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Tuberculosis Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Tuberculosis Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tuberculosis Therapeutics Market Drivers
1.6.2 Tuberculosis Therapeutics Market Restraints
1.6.3 Tuberculosis Therapeutics Trends Analysis
2 Company Profiles
2.1 Aventis Pharmaceuticals
2.1.1 Aventis Pharmaceuticals Details
2.1.2 Aventis Pharmaceuticals Major Business
2.1.3 Aventis Pharmaceuticals Tuberculosis Therapeutics Product and Solutions
2.1.4 Aventis Pharmaceuticals Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Aventis Pharmaceuticals Recent Developments and Future Plans
2.2 Sanofi -Aventis
2.2.1 Sanofi -Aventis Details
2.2.2 Sanofi -Aventis Major Business
2.2.3 Sanofi -Aventis Tuberculosis Therapeutics Product and Solutions
2.2.4 Sanofi -Aventis Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi -Aventis Recent Developments and Future Plans
2.3 Versapharma Incorporated
2.3.1 Versapharma Incorporated Details
2.3.2 Versapharma Incorporated Major Business
2.3.3 Versapharma Incorporated Tuberculosis Therapeutics Product and Solutions
2.3.4 Versapharma Incorporated Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Versapharma Incorporated Recent Developments and Future Plans
2.4 Sigma Pharmaceutical Pty
2.4.1 Sigma Pharmaceutical Pty Details
2.4.2 Sigma Pharmaceutical Pty Major Business
2.4.3 Sigma Pharmaceutical Pty Tuberculosis Therapeutics Product and Solutions
2.4.4 Sigma Pharmaceutical Pty Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Sigma Pharmaceutical Pty Recent Developments and Future Plans
2.5 Novartis AG
2.5.1 Novartis AG Details
2.5.2 Novartis AG Major Business
2.5.3 Novartis AG Tuberculosis Therapeutics Product and Solutions
2.5.4 Novartis AG Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Novartis AG Recent Developments and Future Plans
2.6 Hoffmann-La Roche
2.6.1 Hoffmann-La Roche Details
2.6.2 Hoffmann-La Roche Major Business
2.6.3 Hoffmann-La Roche Tuberculosis Therapeutics Product and Solutions
2.6.4 Hoffmann-La Roche Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Hoffmann-La Roche Recent Developments and Future Plans
2.7 Bayer Health Care
2.7.1 Bayer Health Care Details
2.7.2 Bayer Health Care Major Business
2.7.3 Bayer Health Care Tuberculosis Therapeutics Product and Solutions
2.7.4 Bayer Health Care Tuberculosis Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Bayer Health Care Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Tuberculosis Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Tuberculosis Therapeutics Players Market Share
3.2.2 Top 10 Tuberculosis Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Tuberculosis Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Tuberculosis Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Tuberculosis Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Tuberculosis Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Tuberculosis Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Tuberculosis Therapeutics Revenue by Type (2016-2026)
6.2 North America Tuberculosis Therapeutics Revenue by Application (2016-2026)
6.3 North America Tuberculosis Therapeutics Market Size by Country
6.3.1 North America Tuberculosis Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Tuberculosis Therapeutics Revenue by Type (2016-2026)
7.2 Europe Tuberculosis Therapeutics Revenue by Application (2016-2026)
7.3 Europe Tuberculosis Therapeutics Market Size by Country
7.3.1 Europe Tuberculosis Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tuberculosis Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Tuberculosis Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Tuberculosis Therapeutics Market Size by Region
8.3.1 Asia-Pacific Tuberculosis Therapeutics Revenue by Region (2016-2026)
8.3.2 China Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Tuberculosis Therapeutics Revenue by Type (2016-2026)
9.2 South America Tuberculosis Therapeutics Revenue by Application (2016-2026)
9.3 South America Tuberculosis Therapeutics Market Size by Country
9.3.1 South America Tuberculosis Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tuberculosis Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Tuberculosis Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Tuberculosis Therapeutics Market Size by Country
10.3.1 Middle East & Africa Tuberculosis Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Tuberculosis Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Tuberculosis Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Tuberculosis Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Tuberculosis Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Tuberculosis Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Tuberculosis Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Aventis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Aventis Pharmaceuticals Major Business
Table 8. Aventis Pharmaceuticals Tuberculosis Therapeutics Product and Solutions
Table 9. Aventis Pharmaceuticals Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi -Aventis Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi -Aventis Major Business
Table 12. Sanofi -Aventis Tuberculosis Therapeutics Product and Solutions
Table 13. Sanofi -Aventis Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Versapharma Incorporated Corporate Information, Head Office, and Major Competitors
Table 15. Versapharma Incorporated Major Business
Table 16. Versapharma Incorporated Tuberculosis Therapeutics Product and Solutions
Table 17. Versapharma Incorporated Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Sigma Pharmaceutical Pty Corporate Information, Head Office, and Major Competitors
Table 19. Sigma Pharmaceutical Pty Major Business
Table 20. Sigma Pharmaceutical Pty Tuberculosis Therapeutics Product and Solutions
Table 21. Sigma Pharmaceutical Pty Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 23. Novartis AG Major Business
Table 24. Novartis AG Tuberculosis Therapeutics Product and Solutions
Table 25. Novartis AG Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 27. Hoffmann-La Roche Major Business
Table 28. Hoffmann-La Roche Tuberculosis Therapeutics Product and Solutions
Table 29. Hoffmann-La Roche Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Bayer Health Care Corporate Information, Head Office, and Major Competitors
Table 31. Bayer Health Care Major Business
Table 32. Bayer Health Care Tuberculosis Therapeutics Product and Solutions
Table 33. Bayer Health Care Tuberculosis Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Global Tuberculosis Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 35. Global Tuberculosis Therapeutics Revenue Share by Players (2019-2021)
Table 36. Breakdown of Tuberculosis Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 37. Tuberculosis Therapeutics Players Head Office, Products and Services Provided
Table 38. Tuberculosis Therapeutics Mergers & Acquisitions in the Past Five Years
Table 39. Tuberculosis Therapeutics New Entrants and Expansion Plans
Table 40. Global Tuberculosis Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 41. Global Tuberculosis Therapeutics Revenue Share by Type (2016-2021)
Table 42. Global Tuberculosis Therapeutics Revenue Forecast by Type (2021-2026)
Table 43. Global Tuberculosis Therapeutics Revenue by Application (2016-2021)
Table 44. Global Tuberculosis Therapeutics Revenue Forecast by Application (2021-2026)
Table 45. North America Tuberculosis Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 46. North America Tuberculosis Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 47. North America Tuberculosis Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 48. North America Tuberculosis Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 49. North America Tuberculosis Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 50. North America Tuberculosis Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 51. Europe Tuberculosis Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 52. Europe Tuberculosis Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 53. Europe Tuberculosis Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 54. Europe Tuberculosis Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 55. Europe Tuberculosis Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 56. Europe Tuberculosis Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 57. Asia-Pacific Tuberculosis Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. Asia-Pacific Tuberculosis Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. Asia-Pacific Tuberculosis Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. Asia-Pacific Tuberculosis Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. Asia-Pacific Tuberculosis Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 62. Asia-Pacific Tuberculosis Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 63. South America Tuberculosis Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. South America Tuberculosis Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. South America Tuberculosis Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. South America Tuberculosis Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. South America Tuberculosis Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. South America Tuberculosis Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Middle East & Africa Tuberculosis Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Middle East & Africa Tuberculosis Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Middle East & Africa Tuberculosis Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Middle East & Africa Tuberculosis Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Middle East & Africa Tuberculosis Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 74. Middle East & Africa Tuberculosis Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Tuberculosis Therapeutics Picture
Figure 2. Global Tuberculosis Therapeutics Revenue Market Share by Type in 2020
Figure 3. Isoniazid
Figure 4. Rifampin
Figure 5. Pyrazinamide
Figure 6. Hydrazine Derivatives
Figure 7. Miscellaneous Anti-Tubercular Drugs
Figure 8. Ethambutol
Figure 9. Others
Figure 10. Tuberculosis Therapeutics Revenue Market Share by Application in 2020
Figure 11. Hospital Picture
Figure 12. Pharmacy Picture
Figure 13. Clinics Picture
Figure 14. Others Picture
Figure 15. Global Tuberculosis Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Tuberculosis Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Tuberculosis Therapeutics Revenue Market Share by Region (2016-2026)
Figure 18. Global Tuberculosis Therapeutics Revenue Market Share by Region in 2020
Figure 19. North America Tuberculosis Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Tuberculosis Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Tuberculosis Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Tuberculosis Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Tuberculosis Therapeutics Market Drivers
Figure 24. Tuberculosis Therapeutics Market Restraints
Figure 25. Tuberculosis Therapeutics Market Trends
Figure 26. Aventis Pharmaceuticals Recent Developments and Future Plans
Figure 27. Sanofi -Aventis Recent Developments and Future Plans
Figure 28. Versapharma Incorporated Recent Developments and Future Plans
Figure 29. Sigma Pharmaceutical Pty Recent Developments and Future Plans
Figure 30. Novartis AG Recent Developments and Future Plans
Figure 31. Hoffmann-La Roche Recent Developments and Future Plans
Figure 32. Bayer Health Care Recent Developments and Future Plans
Figure 34. Global Tuberculosis Therapeutics Revenue Share by Players in 2020
Figure 35. Tuberculosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Tuberculosis Therapeutics Revenue Market Share in 2020
Figure 37. Global Top 10 Players Tuberculosis Therapeutics Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Tuberculosis Therapeutics Revenue Share by Type in 2020
Figure 40. Global Tuberculosis Therapeutics Market Share Forecast by Type (2021-2026)
Figure 41. Global Tuberculosis Therapeutics Revenue Share by Application in 2020
Figure 42. Global Tuberculosis Therapeutics Market Share Forecast by Application (2021-2026)
Figure 43. North America Tuberculosis Therapeutics Sales Market Share by Type (2016-2026)
Figure 44. North America Tuberculosis Therapeutics Sales Market Share by Application (2016-2026)
Figure 45. North America Tuberculosis Therapeutics Revenue Market Share by Country (2016-2026)
Figure 46. United States Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Tuberculosis Therapeutics Sales Market Share by Type (2016-2026)
Figure 50. Europe Tuberculosis Therapeutics Sales Market Share by Application (2016-2026)
Figure 51. Europe Tuberculosis Therapeutics Revenue Market Share by Country (2016-2026)
Figure 52. Germany Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Tuberculosis Therapeutics Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Tuberculosis Therapeutics Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Tuberculosis Therapeutics Revenue Market Share by Region (2016-2026)
Figure 60. China Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Tuberculosis Therapeutics Sales Market Share by Type (2016-2026)
Figure 67. South America Tuberculosis Therapeutics Sales Market Share by Application (2016-2026)
Figure 68. South America Tuberculosis Therapeutics Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Tuberculosis Therapeutics Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Tuberculosis Therapeutics Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Tuberculosis Therapeutics Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Tuberculosis Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source